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AbstrAct
The mRNA modification N6-methyladenosine (m6A) is involved in many post-
transcriptional regulatory processes including mRNA stability and translational 
efficiency. However, it is also imperative to correlate these processes with phenotypic 
outputs during cancer progression. Here we report that m6A levels are significantly 
decreased in genetically-defined immortalized and oncogenically-transformed human 
mammary epithelial cells (HMECs), as compared with their primary cell predecessor. 
Furthermore, the m6A methyltransferase (METTL3) is decreased and the demethylase 
(ALKBH5) is increased in the immortalized and transformed cell lines, providing a 
possible mechanism for this basal change in m6A levels. Although the immortalized 
and transformed cells showed lower m6A levels than their primary parental cell line, 
overexpression of METTL3 and METTL14, or ALKBH5 knockdown to increase m6A 
levels in transformed cells increased proliferation and migration. Remarkably, these 
treatments had little effect on the immortalized cells. Together, these results suggest 
that m6A modification may be downregulated in immortalized cells as a brake against 
malignant progression. Finally, we found that m6A levels in the immortalized and 
transformed cells increased in response to hypoxia without corresponding changes in 
METTL3, METTL14 or ALKBH5 expression, suggesting a novel pathway for regulation 
of m6A levels under stress. 
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IntroductIon
For the United States in 2018, it is estimated that 
there will be over 250,000 new cases of breast cancer, 
resulting in 40,000 deaths [1]. Although the 5-year 
survival rate for patients diagnosed with localized 
breast cancer is nearly 99%, patients who present with 
stage IV metastatic breast cancer have a less than 30% 
survival rate [2, 3]. Gene expression profiles of breast 
cancer have been extensively studied, but they provide an 
incomplete picture of the biology driving this progression 
from localized, low-risk disease to aggressive metastatic 
phenotypes. New investigations of post-transcriptional 
and translational pathways that regulate gene expression 
in breast cancer cells are therefore needed to identify novel 
therapeutic targets for suppressing growth and metastasis 
of tumor cells. 
Recently, the mRNA modification N6-methy-
ladenosine (m6A) has been shown to be involved in post-
transcriptional gene regulation and cancer progression. 
Decreases in m6A levels have been directly correlated to 
metastasis and poor patient prognosis in hepatocellular 
carcinoma [4] and disease progression in cervical 
cancer [5]. However, experimental models focused on 
manipulating m6A levels have given conflicting results 
regarding the role of m6A in malignant progression. On 
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one hand, loss of m6A through an increase in ALKBH5, an 
m6A demethylase, led to enhanced breast and glioblastoma 
cancer stem cell self-renewal and growth [6–8]. On the 
other hand, an increase in m6A driven by overexpression of 
the methyltransferase, METTL3, led to increased invasion 
of lung adenocarcinoma cells [9], but inhibited growth of 
renal cell carcinoma cells [10]. Additionally, METTL3 
has also been shown to promote translation in human lung 
cancer cells independent of its m6A methylation activity 
[9]. As the roles for m6A modifications in cancer begin to 
emerge, it will be important to understand the specific role 
that the m6A modification plays in different cancer types 
and at different stages in the development of tumors. 
The m6A modification is the most abundant 
modification in mRNA [11]. This modification has been 
shown to be important for the stability and translational 
efficiency of mRNA [12–17], and is involved in the 
pluripotency of stem cells in embryonic development 
[18–20]. Methyltransferase-like (METTL)-3 and -14, as 
well as Wilms’ tumor associating protein (WTAP) form the 
m6A methyltransferase complex which modifies nascent 
pre-mRNA within the nucleus [21–25]. The enzymatically 
active component of the methyltransferase, METTL3, 
contains an S-adenosyl methionine (SAM) binding 
domain, and utilizes SAM as a substrate to methylate 
target mRNAs that contain a DRACH m6A consensus 
sequence, often found in 3′ UTR’s and around both start 
and stop codons [21, 26–29]. METTL14 lacks catalytic 
activity but participates in mRNA binding/targeting 
[30–32]. WTAP is responsible for the localization of 
the METTL3/14 complex to the nuclear speckle, and 
greatly enhances methyltransferase activity by bringing 
the methyltransferase to the pre-mRNA [21, 22]. m6A 
methylation of mRNA can be reportedly removed by 
alkylation repair homolog 5 (ALKBH5) and fat mass 
and obesity related protein (FTO). Interestingly, a recent 
study suggests that FTO can also demethylate N6,2′-O-
dimethyladenosine (m6Am) raising questions about its 
preferred in vivo substrate [33]. 
Once an mRNA is methylated, it can be bound 
by the YTH family of RNA binding proteins, including 
YTHDF1, YTHDF2, and YTHDC1 [15, 34, 35]. The 
broader consequences of RNA methylation through the 
actions of these and other m6A RNA binding proteins 
are still being investigated. However, YTHDF2 has been 
shown to facilitate degradation of methylated mRNAs by 
transporting them to P bodies [15, 36–38]. Alternatively, 
binding of YTHDF1 increases translational efficiency of 
m6A methylated mRNA [16]. Lastly, YTHDC1 recruits 
splicing factors to regulate splicing of m6A methylated 
mRNA [39]. The interactions between these RNA binding 
proteins is not fully understood, and competition between 
them may yield different fates for the methylated mRNA 
and ultimately for the protein output.
As mentioned previously, m6A methylation of 
RNA has recently been correlated with a number of 
phenotypic changes in a variety of cancers including 
breast cancer [4–10]. Many of these phenotypic changes 
are the result of changing protein expression of either 
the m6A methyltransferases, demethylases or RNA 
binding proteins. These studies have shown that m6A 
has a functional significance in cancer, but there remain 
incomplete connections between m6A modifications and 
cancer cell phenotypes. For example, tumors can quickly 
outgrow their blood supply during cancer progression and 
they therefore must adapt to hypoxic conditions. Hypoxic 
breast cancer cells adapt to these conditions through 
Hypoxia Inducible Factor (HIF)-mediated angiogenesis 
[40]. Not only does HIF increase vascularization of the 
tumor to increase blood and oxygen supply, but it is 
also known to promote metastasis of the cells [41–43]. 
Interestingly, ALKBH5, an m6A demethylase, is also 
regulated by HIF [44]. Recently, it was reported that 
a HIF-regulated decrease in m6A through an increase 
in ALKBH5 and/or ZNF217 expression maintains 
pluripotency of breast cancer stem cells in several 
established breast cancer cell lines [7, 45]. Furthermore, 
we recently reported that hypoxia led to an increase 
in m6A mRNA levels in HEK-293T cells, leading to 
increased stability and recovery of translational efficiency 
after re-oxygenation [17]. Because hypoxia both regulates 
m6A levels and promotes metastasis in breast cancer cells, 
it is important to understand if m6A might have a role in 
hypoxia- induced breast cancer metastasis. 
Our current study aimed to define the landscape of 
m6A modification during breast cancer development and 
progression. Because cancers have many diverse mutations 
and alterations to gene regulation, it has been difficult 
to pinpoint exactly which changes introduce aggressive 
phenotypic behavior. For this reason, we chose to use a 
genetically-defined breast cancer progression model for 
these studies. In this model, three cell types are utilized: 
primary Human Mammary Epithelial cells (HMECs), 
HMECs immortalized through the stable expression of 
hTERT, p53DD, cyclin D1, CDK4R24C, and C-MYCT58A, and 
a further transformed line expressing with H-RASG12V in 
addition to the above alterations (Supplementary Figure 1) 
[46, 47]. 
Using this model of breast cancer development, 
we found that immortalization resulted in reduced m6A 
levels as well as significant down-regulation of the m6A 
methylation complex (METTL3/14) and up-regulation of 
the primary demethylase (ALKBH5). These modifications 
were maintained, but not enhanced, during malignant 
transformation. Experimentally increasing the level of 
m6A modification led to a more malignant phenotype in 
transformed cells, but not their immortalized precursors. 
Finally, we found that stress from hypoxia stimulated 
an increase in m6A levels in both immortalized and 
transformed cells through a pathway that is independent of 
METTL3/14 and ALKBH5 expression levels, but reliant 
on HIF. Surprisingly, increasing m6A levels led to a more 
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malignant phenotype in transformed cells, but not their 
immortalized precursors. 
results
We first investigated whether m6A levels were 
altered in our breast cancer progression model, and 
what effect hypoxia had on mRNA m6A content in the 
HMEC cell lines. HMEC cells (primary, immortalized, 
and transformed) were incubated for 24 hours under 
normoxic or hypoxic (1% O2) conditions. PolyA
+ 
mRNA was isolated by oligo-dT selection followed by 
ribosomal RNA (rRNA) depletion, and after digestion 
to individual nucleotides, ultra-high-performance 
liquid chromatography and tandem mass spectrometry 
(UPLC-MS/MS) were used to quantify various RNA 
modifications in the mRNA enriched samples. As shown 
in Figure 1, normoxic m6A levels were decreased in both 
the immortalized and transformed cell lines in comparison 
to the primary HMECs. While hypoxia had no effect 
on the m6A level in the primary cells, it significantly 
increased m6A levels in immortalized and transformed 
cells (Figure 1). This is consistent with our prior report 
that hypoxia raises m6A levels in the transformed 
HEK293T cell line [17]. Other mRNA modifications, 
including 5-methylcytidine, remained unchanged in this 
model of breast cancer progression or were not influenced 
by hypoxia, (Supplementary Figure 2), suggesting that 
m6A levels are particularly important in the progression 
to oncogenic transformation and the hypoxia response.
Protein levels of m6A methyltransferases and 
demethylases
To investigate the dynamic response of m6A to 
cellular transformation as well as hypoxia, we measured 
RNA and protein levels of the m6A-associated enzymes 
and effector proteins involved with m6A, including 
methyltransferases, demethylases, and RNA binding 
proteins, many of which exhibited notable changes upon 
immortalization and oncogenic transformation of the 
HMEC cells (Figure 2). Protein and RNA expression for 
the enzymatically active subunit of the methyltransferase, 
METTL3, was decreased in immortalized and 
transformed cells, but METTL14 was increased (Figure 2, 
Supplementary Figure 3). In addition, ZNF217 protein, 
which is known to sequester METTL3 and prevent its 
methyltransferase activity [48], is also increased in the 
immortalized and transformed cells. RNA and protein 
expression for demethylases ALKBH5 and FTO were also 
increased in the immortalized and transformed cells, which 
is concordant with the decreased m6A levels in these 
cells. This data suggests that the loss of m6A observed 
in the transformed cells may be due to an increase in 
ZNF217, a loss of the methyltransferase, METTL3, and 
an increase of the demethylases, ALKBH5 and FTO. 
Figure 1: mrnA m6A levels are decreased in immortalized and transformed HMecs but increased by hypoxia. LC-
MS/MS of mRNA nucleosides isolated from primary, immortalized, and transformed HMECs grown in normoxia or hypoxia (1% O2) for 
24 hours. Values represent the amount of m6A relative to total Adenosine content. *P ≤ 0.05, @P ≤ 0.1 by paired Student’s t-test. Error bars 
represent standard error of the mean (SEM) of 3 experiments.
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Hypoxia, however, had very little effect on the protein 
levels. Therefore, the increase in m6A levels in response 
to hypoxia is not explained by the observed protein levels 
of the methyltransferases or demethylases, suggesting that 
it must be due to some other process.
The m6A binding proteins YTHDF1, YTHDF2 
and YTHDC1 were also altered in the immortalized and 
transformed cells lines. YTHDF1 levels were increased, 
but YTHDF2 levels were decreased in the immortalized 
and transformed cells. The blots for YTHDC1 interestingly 
contained a shift from a lower molecular weight (the correct 
expected molecular weight) to a much higher molecular 
weight (the observed molecular weight given in the details 
of the antibody). Given the known roles of YTHDF1 and 2 
[12, 16], the switch from high YTHDF2 and low YTHDF1 
expression to high YTHDF1 and low YTHDF2 suggests that 
m6A modifications in the immortalized and transformed 
cells are no longer primarily directing degradation of 
mRNA, but rather increasing translational efficiency. 
Notably, RNA expression of YTHDF2 was strongly 
increased in immortal and transformed cells, despite the 
decreased protein levels (Supplementary Figure 3). 
differential methylation of specific mrnAs in 
response to hypoxia
Although protein expression levels of the m6A 
methyltransferases and demethylases could not explain 
why m6A is increased in hypoxia for the immortalized 
and transformed HMECs, we have previously shown that 
m6A itself can stabilize certain mRNAs under hypoxic 
conditions, including Glut1, Jun, Myc, and DUSP1 [17]. 
Therefore, it is possible that the hypoxic increase in 
m6A levels is simply due to a relative accumulation of 
mRNAs that have been stabilized by m6A modifications. 
In order to test this possibility, we used m6A RNA 
immunoprecipitation (MeRIP) to assay previously-
identified mRNA targets for increased m6A levels after 
24 hours of hypoxic conditions [17]. This approach 
allows for quantification of changes in m6A content by 
Figure 2: Protein expression of m6A methyltransferases, demethylases and rnA binding proteins changes during 
HMec immortalization/transformation. Western blots of 50 µg of protein lysates from normoxic (N) or hypoxic (H) primary, 
immortalized, and transformed HMECs. (Representative of 3 experiments).
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normalizing the amount of MeRIP-captured RNA to the 
amount of input RNA for each sample, determining a 
percentage of m6A methylated mRNA for each species. 
These percentages can then be compared between different 
conditions (normoxia and hypoxia) to determine the effect 
of those conditions on m6A levels in specific mRNAs. In 
the transformed HMEC line, upon exposure to 24 hours 
of hypoxia, m6A content was significantly increased 
in transcripts for Glut1, Jun, VHL, and Dusp1, but not 
eEF1A1 (Figure 3A, blue bars). These results extend 
our previous findings in 293T cells, which also showed 
that these transcripts have increased m6A content in 
response to hypoxia [17]. MeRIP from immortalized cells 
showed a similar trend, but primary HMEC cells showed 
minimal differences in m6A levels for these transcripts 
(Supplementary Figure 4). These data demonstrate a 
specific increase in the m6A of these mRNAs from 
transformed HMECs in response to 24 hours hypoxic 
exposure. 
We next tested whether 24 hours of hypoxic 
exposure resulted in increased methylation of newly 
transcribed RNA in the transformed HMECs. A uridine 
analog, 4-thiouridine (4sU), was added to the culture 
media for the final hour of exposure, to be incorporated 
into all newly transcribed RNA. After isolation, this 
newly transcribed RNA was biotinylated and separated 
from old (unlabeled) mRNA using streptavidin beads. 
After elution of the newly transcribed RNA from the 
streptavidin beads, MeRIP was then used to pull down 
m6A methylated RNA from this population of new RNA. 
In contrast to the total mRNA, newly transcribed mRNA 
had less m6A methylation in hypoxia than normoxia 
(Figure 3A, orange bars), suggesting that methylation 
of these newly transcribed RNAs was not increased at 
24 hours of hypoxic exposure. This data then also suggests 
that the increase in m6A seen after 24 hours of hypoxic 
exposure was not due to a sustained increase in the 
methylation of newly transcribed mRNA, but more likely 
an accumulation of pre-existing, methylated mRNAs.
HIF controls hypoxic m6A levels in specific 
targets
To further investigate how m6A was increased under 
hypoxia, we wanted to determine if the HIF transcriptional 
response was involved. HIF-1α and HIF-2α were 
simultaneously knocked down via siRNA in transformed 
cells which were then exposed to 24 hours of hypoxia. 
Knockdown of HIF-1α and HIF-2α was confirmed via 
western blot analysis (Supplementary Figure 5). m6A 
content in individual mRNAs were measured once again 
by MeRIP followed by RT-qPCR. Knockdown of HIF-1α 
and HIF-2α prevented the hypoxic increase in m6A levels 
in many of our targets including Glut1, VHL, and Dusp1 
(Figure 3B). This suggests that the increase in m6A in 
hypoxia is at least partially due to the hypoxic induction 
of HIF.
Phenotypic effect of m6A modulation 
We then sought to determine the differences in 
m6A levels between progressive stages of a genetically-
defined breast cancer model, but also to understand 
if changes in m6A levels during pre-malignant 
immortalization of primary cells has a functional role 
in regulating the response to hypoxia. Because hypoxia 
has been reported to induce cell migration, we measured 
changes in migratory potential in immortalized and 
transformed cells in response to hypoxia. Exposure of 
the transformed HMECs to 24 hours of hypoxia led to 
increased cell migration when compared to normoxia 
(Figure 4A), but surprisingly had little effect on migration 
of the immortalized cells (Figure 4B). Simultaneous 
knockdown of METTL3 and METTL14 via siRNA in 
the transformed cells significantly reduced the hypoxic 
increase (Figure 4A), suggesting that m6A is directly 
involved in this phenotypic change. Furthermore, 
increasing m6A levels by simultaneous overexpression 
of the m6A methyltransferases METTL3 and 14 or by 
knockdown of the demethylase ALKBH5 (Figure 4A) in 
normoxic conditions also led to an increase in migration 
of the transformed cells, further supporting a role for 
increased m6A in this phenotypic change. In contrast 
to the transformed cells, no significant differences were 
seen in the migration of the immortalized cells in any of 
these conditions when compared to controls (Figure 4B). 
Confirmation of METTL3/14 overexpression and 
ALKBH5 knockdown is shown in Supplementary Figure 5 
and representative scratch assay images can be found in 
Supplementary Figure 6. 
Interestingly, overexpression of METTL3 and 14 
increased proliferation in both the transformed (Figure 5A) 
and immortalized (Figure 5B) cells. Although the effect 
was not robust and only significant at specific time points 
for each cell line, it again suggests that increases in 
cellular m6A levels can alter the phenotypes of the breast 
cancer cells. 
summary
Our findings indicate that mRNA m6A methylation 
levels decrease during immortalization of primary 
HMECs. Consistent with our previous findings, hypoxia 
increases mRNA m6A levels in both immortalized 
transformed cells [17]. These increases in m6A in hypoxia 
are regulated by HIF, and are not due to increased 
protein levels of the methyltransferase or methylation 
rates. Increasing m6A methylation by overexpressing 
methyltransferases and/or hypoxic exposure in the 
transformed cells, increased proliferation and migration, 
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while only affecting proliferation in the immortalized 
cells, indicating that pre-malignant and malignant cells 
may utilize m6A to in different ways.
dIscussIon
Although gene expression in breast cancer has 
been extensively studied, the contribution of mRNA 
modifications to breast cancer progression is not known. 
An advantage to using a genetically-defined breast cancer 
model is that it limits the heterogeneity that is inherent 
to patient-derived samples which may aid in uncovering 
the mechanisms underlying the phenotypic changes driven 
by increased m6A. Studies involving RNA modifications, 
including the m6A modification, may lead to a better 
understanding of gene regulation in cancers. 
In this study, we show that the m6A modification 
of mRNA decreases after immortalization and subsequent 
oncogenic transformation of primary HMECs maintained 
under normoxia. These results provide a more detailed 
view of cancer progression, and support prior findings 
that low levels of m6A modification correlate with 
a more oncogenic or aggressive cellular phenotype. 
However, our results also show that hypoxia drives m6A 
modification of mRNA back to primary cell levels. Our 
findings differ from previous reports that have shown total 
RNA m6A levels in breast cancer cell lines decrease in 
hypoxia conditions through HIF mediated induction of 
Figure 3: m6A methylation of specific mrnAs increases in transformed HMecs exposed to hypoxia in a HIF 
dependent manner. (A) MeRIP of 100 ng of total mRNA (Blue Bars) or newly transcribed mRNA (Orange Bars) from transformed 
HMECs. Cells were grown in normoxic or hypoxic conditions for 24 hours and mRNA was quantified by qRT-PCR. Fold enrichments 
calculated from immunoprecipitated RNA levels normalized to input RNA and expressed as a ratio of hypoxia/normoxia. *P ≤ 0.05 by 
unpaired Student’s t-test represents increased m6A levels in hypoxia compared to normoxia. #P ≤ 0.05 represents a decrease in m6A in 
newly transcribed RNAs in hypoxia as compared to total RNAs in hypoxia. Error bars represent SEM of 3 experiments. (b) MeRIP of 
100 ng of mRNA from transformed HMECs. Cells were transfected with control (Neg KD) or HIF-1α and HIF-2α siRNA (HIF KD) and 
grown for 48 hours before being exposed to either normoxic or hypoxic conditions for 24 hours. RNA was quantified by qRT-PCR. Fold 
enrichments calculated from immunoprecipitated mRNA levels normalized to input RNA and expressed as a ratio of hypoxia/normoxia. 
*P ≤ 0.05 by unpaired Student’s t-test represents increased m6A levels in hypoxia compared to normoxia. #P ≤ 0.05 between control and 
HIF KD by unpaired Student’s t-test. Error bars represent SEM of 4 experiments.
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the demethylase ALKBH5 and/or METTL3 sequestration 
by ZNF217 [7, 45]. These reports indicated that hypoxia 
induces a breast cancer stem cell phenotype through the 
decrease in m6A. The results seen here differ from these 
previous reports possibly due to differences in model 
systems, and hence expressed genes. For example, the 
previous reports show that m6A levels in specific mRNAs, 
including Nanog, is decreased in hypoxia. However, 
Nanog mRNA is not highly expressed in our cell lines 
and no differences in its m6A levels were observed (data 
not shown). In addition, the previous studies also used 
total RNA rather than mRNA to measure differences in 
global m6A levels, so changes in noncoding RNA species 
including ribosomal RNA may explain the differences in 
those studies. 
To understand the mechanism by which m6A levels 
are regulated in our model system, protein expression 
of the methyltransferase, demethylases, and m6A RNA 
binding proteins were measured. Interestingly, the 
enzymatically active subunit of the methyltransferase 
complex, METTL3, is decreased in the immortalized 
and transformed cells, and ZNF217 which sequesters 
METTL3 is increased. Additionally, the two known 
m6A demethylases, ALKBH5 and FTO, increase in 
the immortalized and transformed cells. Therefore, it 
is possible that the decrease in m6A methylation in the 
immortalized and transformed cells may be due to a loss 
in methylation potential and an increase in demethylation 
potential. In future experiments, it would be interesting 
to investigate which of these expression changes are 
necessary and/or sufficient for the m6A changes observed.
In addition to effects on the m6A enzymes, protein 
expression of m6A specific RNA binding proteins also 
change in the immortalized and transformed cells. 
YTHDF2, an m6A RNA binding protein which leads to 
degradation of the methylated RNA [15, 36], decreased 
Figure 4: m6A levels impact cellular migration in transformed, but not immortalized HMecs. Wound healing scratch 
assay of transformed (A) and immortalized (b) HMECs. HMECs were transfected with siRNA targeting METTL3 and METTL14 (M3/14 
KD), plasmids overexpressing METTL3 and METTL14 (METTL3/14 OE), plasmid expressing ALKBH5 shRNA (ALK KD), or control 
siRNAs/plasmids and allowed to grow to confluency. After 8 hours of serum starvation, a scratch was made with a p200 tip, cells were 
washed and initial pictures (0 Hr) taken. Cells were then incubated in serum free media in either normoxic or hypoxic conditions for 
24 hours before a second set of pictures was taken (24 Hr). Migration was quantified by measuring the area of cell coverage of three 
representative fields at 0 and 24 hours. *P ≤ 0.05 by Unpaired Student’s t-test. Error bars represent SEM of 3–4 experiments.
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in the immortalized and transformed cells. In contrast, 
YTHDF1, another m6A specific RNA binding protein 
involved in methylated mRNA translational efficiency 
increases in the immortalized and transformed cells [16]. 
These contrasting changes in RNA binding proteins 
suggest that the remaining methylated RNA have increased 
translational efficiency through increased YTHDF1 levels 
and an increase in stability due to a decrease in YTHDF2 
levels. The RNA binding protein YTHDC1 interestingly 
appears expressed at a higher molecular weight in the 
immortalized and transformed cells. This may possibly 
be due to dimerization of YTHDC1, however this has not 
been confirmed. 
We also observed that hypoxia did not lead to 
changes in any of the aforementioned proteins. Because the 
increase of m6A in hypoxia cannot be explained by protein 
levels of methyltransferases, demethylases, or ZNF217, 
we sought an alternative mechanism for this change. 
Our group has previously reported that increased m6A 
methylation in hypoxia leads to stabilization of mRNAs 
[17]. Therefore, it is possible that the increase in m6A 
methylation is due to stabilization and accumulation of 
methylated mRNAs. It is also possible that upon hypoxic 
exposure methylation rates of newly transcribed RNA 
are increased or that increased methylation (or decreased 
demethylation) of mature mRNA is occurring within 
Figure 5: Mettl3 and 14 overexpression leads to increased proliferation of transformed and immortal HMecs. 
Transformed (A) and immortalized (b) HMECs were transfected with either a control GFP expressing plasmid or plasmids overexpressing 
METTL3 and METTL14 (M3/14). 48 hours after transfection, cells were re-plated at 0.5 × 106 cells/well of a 6 well plate and allowed 
to recover for 16 hours. Cells were then detached by trypsin at each time point (0, 24, or 48 hours), and counted in a hemocytometer to 
determine cell number.  *P ≤ 0.05 by paired Student’s t-test. Error bars represent SEM of 3 experiments.
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the cytoplasm, as has recently been shown in neuronal 
cells [49]. However, a recent study has shown that m6A 
methylation is not dynamic within the cytoplasm, which 
would suggest that neither methylation nor demethylation 
levels are altered on mature mRNA [25]. 
We investigated whether prolonged hypoxic 
exposure increased the methylation of newly transcribed 
RNA. These experiments showed that after 24 hours of 
hypoxia, methylation of newly transcribed RNA was 
not increased, and in fact trended towards a decrease of 
m6A in newly transcribed RNA. Given this observation 
and our previous findings that m6A containing mRNA 
are stabilized under hypoxia, it seems more likely that 
the increase in m6A levels is due to the accumulation 
of the stabilized mRNA. This scenario still leaves open 
the possibility of an increase in newly transcribed RNA 
methylation earlier in the hypoxic exposure that then 
returns to baseline or below by 24 hours. However, even 
in this scenario, the increased m6A levels in those RNAs 
are likely maintained through the stabilization of those 
mRNAs, a possibility that we are currently exploring.
Because the hypoxic response through HIF is 
crucial for survival and tumorigenesis of cancer cells 
under hypoxic conditions, the effect of HIF on m6A levels 
in hypoxia was measured. Previous reports using breast 
cancer stem cells have shown that hypoxic activation 
of HIF led to decreased RNA methylation through HIF-
mediated induction of the demethylase ALKBH5 and 
METTL3 suppressor ZNF217 [7, 45]. However, in our 
model system of differentiated human mammary epithelial 
cells there is an increase in m6A in hypoxia, rather than 
a decrease, and no change in either ALKBH5 or ZNF217 
expression levels. Furthermore, knockdown of HIF 
decreased hypoxic m6A levels in many of our specific 
targets including Glut1, Dusp1, and VHL, suggesting that 
HIF transcriptional activity is involved in the increase 
of m6A in these targets. The conflicting data with the 
previous report may be explained through a difference 
in model system. However, it would also be informative 
to investigate the role of ZNF217 in our HMEC-based 
system to see if it interacts with METTL3 and the m6A 
system and whether that interaction is regulated during 
breast cancer progression. Indeed, these results, along with 
contrasting effects of m6A in other cancer types highlights 
the importance of understanding the m6A modification in 
all cancer systems at various stages of disease.
Understanding mechanisms behind m6A 
methylation is important in breast cancer, as it may lead to 
a better understanding of the cancer itself. However, it is 
also important to observe the phenotypic effects that m6A 
modulation has on breast cancer. As stated previously, 
immortalization and oncogenic transformation of HMEC 
cells led to a decrease in m6A methylation. It therefore 
seemed likely that an increase of m6A in these transformed 
cells would drive cells back toward a more primary-cell 
phenotype. However, increasing m6A levels either through 
hypoxia or METTL3/14 overexpression in the transformed 
cells increased proliferation and migration of those cells. 
Thus, it appears likely that an increase in m6A either 
through methyltransferase overexpression or an as of yet 
unidentified HIF-mediated mechanism promotes a more 
malignant phenotype. It is also possible that METTL3 
could be acting in an m6A-independent manner as has 
been shown in lung cancer cells [9]. However, because 
ALKBH5 knockdown and hypoxia both recapitulated 
the METLL3/14 overexpression results, it would suggest 
that it is the increase in m6A itself that was underlying 
the phenotypic changes. Interestingly, the immortalized 
cells did not show the same response as transformed cells, 
suggesting that the increased m6A was working in tandem 
with expression of oncogenic HRasG12V (the only 
transgene to differ between the two cell lines) in order to 
alter these phenotypes. Future studies will investigate this 
relationship between Ras transformation and the role of 
m6A in promoting tumor phenotypes.
Overall, this study demonstrates that m6A 
methylation is important for the phenotypic progression 
of breast cancer in a genetically-defined model. Hypoxia 
appears to play a role in this progression through 
increases in mRNA m6A levels in breast cancer through 
HIF activation. This hypoxic response can be mimicked 
in normal cells by experimentally raising m6A levels. 
While it is clear m6A plays a role in these processes, it is 
imperative that we now identify the mRNA that are being 
affected and determine the impact on gene expression in 
order to understand the underlying biological causes for 
these phenotypic changes. 
MAterIAls And MetHods
cell lines
HMEC Primary cell lines cells were obtained 
directly from Lonza (Walkersville, MD) and maintained 
in Mammary Epithelial Basal Medium (MEBM) (Lonza) 
and supplemented with Mammary Epithelial Cell Growth 
Medium (MEGM) BulletKit (Lonza) along with 2 mM 
Glutamine (Corning/Mediatech), and 1× Pen/Strep 
(Corning/Mediatech) and passaged when approximately 
85–90% confluent. Immortalized and transformed cells 
were gifts from Jack Keene’s lab [46]. Immortalized 
and transformed cells were maintained in MEGM+10% 
FBS. Cells were tested for mycoplasma upon receipt. For 
experiments, cells were plated on 10 cm dishes (CytoOne, 
USA Scientific, Orlando, FL) allowed to attach/recover 
for 18–24 hours. The next day, the media was removed 
and replaced with fresh media. Hypoxic treatments were 
carried out in a Ruskin In Vivo 400 Hypoxia Hood (The 
Baker Company, Sanford, ME) maintained at 37° C, 5% 
CO2, 70% humidity and 1% oxygen. All other chemical 
reagents were obtained from Sigma-Aldrich (St. Louis, 
MO) unless otherwise specified. 
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rnA extraction
Trizol (Life Technologies, Carlsbad, CA) was used 
for all RNA extractions according to the manufacturer’s 
protocol. RNA was further purified and treated with 
RNase-Free DNase I (Life Technologies) using PureLink 
RNA Mini Kit (Life Technologies). For RNA extraction 
from ribonucleoprotein immunoprecipitations (RNP-IP) 
and sucrose gradients, GlycoBlue (Life Technologies) 
was added as a carrier during the precipitation step. RNA 
purity and quantity was determined via NanoDrop 1000 
(ThermoFisher Scientific, Waltham, MA).
lc-Ms/Ms of PolyA+ rnA
PolyA+ RNA was first purified from total RNA 
through oligo-dT selection using a Poly(A)Purist-MAG 
magnetic mRNA Purification Kit (Life Technologies) 
followed by ribosomal RNA depletion using RiboMinus 
Eukaryote Kit (Life Technologies) according to the 
manufacturer’s protocols. Purified PolyA+ RNA 
was digested to individual nucleosides and modified 
nucleosides were quantified as previously described 
[50]. Briefly, digestion was performed with nuclease 
P1 (Sigma, 2 U) in buffer containing 25 mM NaCl and 
2.5 mM ZnCl2 for 2 h at 37° C, followed by incubation 
with Antarctic Phosphatase (NEB, 5 U) for an additional 2 
h at 37° C. Nucleosides were then separated and quantified 
using UPLC-MS/MS as previously described [51], except 
acetic acid replaced formic acid in the mobile phase.
Western blots
Whole cell lysates were prepared in whole cell 
extract buffer (WCEB: 50 mM Tris pH 7.4, 150 mM NaCl, 
5 mM EDTA, 0.1% SDS, and complete protease inhibitor 
(Promega, Madison, WI)). Equal amounts of protein 
(30–50 μg) were electrophoresed on a mini-PROTEAN 
any KD acrylamide gel (Bio-Rad Laboratories, Hercules, 
CA) and transferred to Hybond ECL nitrocellulose 
(GE Healthcare, Chicago, IL). Transfer was verified 
via Ponceau S staining then blot was blocked with 
5% nonfat dry milk (LabScientific, Highlands, NJ) in 
Tris buffered saline with 0.1% Tween 20 (TBST) for 
one hour at room temperature, followed by primary 
antibody in blocking buffer overnight at 4° C. After 
washing extensively with TBST, blots were incubated 
for 1–2 hours at room temperature with appropriate anti-
mouse (GE Healthcare), anti-rabbit (GE Healthcare), 
or Rabbit anti-goat (Novus Biologicals, Littleton, CO), 
washed again with TBST, detected using Bio-Rad Clarity 
Western ECL Substrate (Bio-Rad Laboratories), and 
imaged via MYECL Imager (Thermo Scientific). Primary 
Antibodies used and their concentrations can be found in 
Supplementary Table 3.
m6A mrnA immunoprecipitation (MerIP)
m6A Ribonucleoprotein Immunoprecipitation 
reactions were performed by first isolating PolyA+ RNA 
from normoxic and hypoxic cells. Protein G Dynabeads 
(Thermo Fisher Scientific, Baltics UAB) were washed 
3× in 1 mL of IPP buffer (10 mM Tris-HCL pH7.4, 
150 mM NaCl, 0.1% NP-40). 25 µl of beads required per 
IP. Anti-N6-methyladenosine mouse monoclonal antibody 
(EMD Millipore, Temecula, CA, MABE1006) was added 
to the beads (5 µg/IP) and brought up to 1mL with IPP 
buffer. Bead mixture was tumbled for 16 hours at 4° C. 
Beads were washed 5× with IPP buffer and 100 ng of 
PolyA+ RNA was added to the beads along with 1 mM 
DTT and RNase out. The mixture was brought up to 500 µl 
with IPP buffer. Bead mixture was tumbled at 4° C for 
4 hours. Beads were washed 2× in IPP buffer, placed in 
to a fresh tube, and washed 3× more in IPP buffer. m6A 
RNA was eluted off the beads by tumbling 2× with 125 µl 
of 2.5 mg/mL N6-Methyladenosine-5′-monophosphate 
sodium salt (CHEM-IMPEX INT’L INC., Wood Dale, 
IL). Supernatant was added to Trizol-LS followed by RNA 
isolation as per manufacture’s protocol. Final RNA sample 
was brought up in 10 µl of water.
Pcr for MerIP
Reverse transcription was performed on 10 µl m6A 
PolyA+ RNA from the MeRIP with the iScript cDNA 
synthesis kit (Bio-Rad Laboratories, Hercules, CA). After 
diluting cDNA two-fold, quantitative real-time PCR was 
performed using a Roche Lightcycler 96 with Fast Start 
Essential DNA Green (Roche Diagnostics Corporation, 
Indianapolis, IN) and primers from Integrated DNA 
Technologies, Inc. (Coralville, Iowa). Primers used 
are listed in Supplementary Table 1. Primer efficiency 
was verified to be over 95% for all primer sets used. 
Quantification of mRNA from the MeRIP was carried 
out via ΔCT analysis against non-immunoprecipitated 
input RNA. All real-time PCR primer sets were designed 
so the products would span at least one intron (>1 kb 
when possible), and amplification of a single product was 
confirmed by agarose gel visualization and/or melting 
curve analysis.
sirnA transfections 
Either a negative siRNA (Silencer; Life Technologies, 
Carlsbad, CA) or HIF-1α and HIF-2α siRNAs or METTL3 
and METTL14 siRNAs (Qiagen, Germantown, MD) 
were transfected using Lipofectamine RNAi Max per 
manufacturer’s protocol (Life Technologies). siRNAs used 
can be found in Supplementary Table 2. Cells were incubated 
for 72 hours post-transfection with the last 24 hours in either 
normoxic or hypoxic conditions as indicated. 
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Plasmid transfections
Either a negative control plasmid, shRNA scramble 
control, ALKBH5 psi-U6 shRNA construct (GeneCopoeia, 
Rockville, MD) or a METTL3 and METTL14 flag 
tagged construct given by Dr. Jing Crystal Zhao [19] was 
transiently transfected in immortalized and oncogenically 
transformed HMEC cells using Lipofectamine 2000 (Life 
Technologies) in 6 well plates (USA Scientific). Cells 
were incubated for 48 hours post-transfection before 
proliferation or scratch assays.
scratch assays
48 hours after transfection, cells were serum starved 
8 hours prior to the scratch. Afterwards, a scratch was 
made with a p200 pipette tip (USA Scientific), and cells 
were washed 2× with Dulbecco’s Phosphate Buffered 
Saline (DPBS) (Corning) and fresh serum free media 
added. Pictures were taken at 0 and 24 hours and wound 
healing determined by measuring the percentage of the 
visible area that was covered by cells. 
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m6A: N6-methyladenosine; HMECs: human 
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